Other News To Note
Monday, December 19, 2011
Galectin Therapeutics Inc., of Newton, Mass., presented a poster at the European Association for the Study of the Liver Special Conference on Liver Transplantation in Lisbon, Portugal, showing that its galectin inhibitor candidate GR-MD-02 reversed fibrosis in mouse models of steatohepatitis and prevented collagen deposits in mice treated before fibrotic cells formed.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.